Hera BioLabs

Hera Biolabs is an innovative preclinical service and technology provider with novel gene-editing and rat model creation technologies. We created the SRGTM rat, the first commercially available highly immunocompromised rat model, which has been validated for oncology and used routinely for human tumor xenograft studies (OncoRat). We also have our own proprietary gene-editing technologies, piggyBac transposon and the Cas-CLOVER targeted nuclease system, platforms used for cell-line modification and animal model creation. Hera makes available to researchers in academia and industry our gene-editing technologies and products, as well as our SRG rat. Hera also provides services in these areas, performing cell...

Preclinical oncology services,cancer xenografts,humanized immune system rodents,immuno-oncology,srg rat,gene editing,patient derived xenografts pdx,nsg mice,nog mice,transgenic rodent creation,piggybac,and cas-clover

Hera biolabs operates in the Biotechnology research industry.

Hera biolabs's revenue is 11m - 100m

Hera biolabs has 11 - 50 employees.